Lena Lemke
Holzkirchen, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Correction to: Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: April 28, 2025
Comparing anti-drug antibody signal-to-noise ratios to assess immunogenicity and interchangeability in adalimumab biosimilar studies.
Journal: Expert opinion on biological therapy
Published: November 15, 2024
Efficacy, Safety, and Immunogenicity of SDZ-ADL, an Adalimumab Biosimilar, in Biologic-Naïve and Switched Patients with Immune-Mediated Inflammatory Diseases: A Literature Review.
Journal: Advances in therapy
Published: September 06, 2024
'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Journal: Advances in therapy
Published: December 18, 2023
A plain language summary describing how two different concentrations of GP2017, a biosimilar adalimumab medicine, are associated with similar drug levels within the body.
Journal: Immunotherapy
Published: November 30, 2023
Signal-to-noise ratio to assess magnitude, kinetics and impact on pharmacokinetics of the immune response to an adalimumab biosimilar.
Journal: Bioanalysis
Published: November 30, 2023
GP2017-HCF, a high concentration formulation, demonstrates similar pharmacokinetics, immunogenicity and safety to GP2017, an approved adalimumab biosimilar.
Journal: Expert opinion on biological therapy
Published: August 30, 2022
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADMYRA and ADACCESS).
Journal: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy
Published: January 28, 2021
Differences in immunogenicity associated with non-product related variability: insights from two pharmacokinetic studies using GP2017, an adalimumab biosimilar.
Journal: Expert opinion on biological therapy
Published: April 20, 2019
GP2017, an adalimumab biosimilar: pharmacokinetic similarity to its reference medicine and pharmacokinetics comparison of different administration methods.
Journal: Expert opinion on biological therapy
Published: January 31, 2019
Showing 1-10 of 10
Last Updated: 09/26/2026